{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:09:34Z","timestamp":1772791774687,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.retram.2022.103348","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T14:40:01Z","timestamp":1650465601000},"page":"103348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preclinical study of a DNA vaccine targeting SARS-CoV-2"],"prefix":"10.1016","volume":"70","author":[{"given":"Hiroki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Otera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuko","family":"Kubota-Koketsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Shioda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Arase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Nakamaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Ide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2406-5824","authenticated-orcid":false,"given":"Akiko","family":"Tenma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Ehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehisa","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Amaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Chono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Mineno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Komatsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-3601","authenticated-orcid":false,"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7830","key":"10.1016\/j.retram.2022.103348_bib0001","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"6499","key":"10.1016\/j.retram.2022.103348_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.retram.2022.103348_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - preliminary report","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0004","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2022.103348_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.retram.2022.103348_bib0007","article-title":"Covid-19: where are we on vaccines and variants?","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.retram.2022.103348_bib0008","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.retram.2022.103348_bib0009","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"issue":"19","key":"10.1016\/j.retram.2022.103348_bib0010","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanjuan","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0011","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","article-title":"DNA vaccines: progress and challenges","volume":"175","author":"Donnelly","year":"2005","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.retram.2022.103348_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.retram.2022.103348_bib0013","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.drudis.2021.06.008","article-title":"Methods to improve the immunogenicity of plasmid DNA vaccines","volume":"26","author":"Eusebio","year":"2021","journal-title":"Drug Discov Today"},{"issue":"21","key":"10.1016\/j.retram.2022.103348_bib0014","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/sj.gt.3302569","article-title":"Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure","volume":"12","author":"Franquesa","year":"2005","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.ki.5001510","article-title":"HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms","volume":"70","author":"Herrero-Fresneda","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.retram.2022.103348_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0017","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1038\/s41598-021-85202-9","article-title":"SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals","volume":"11","author":"Yoshida","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0018","doi-asserted-by":"crossref","first-page":"e87305","DOI":"10.1371\/journal.pone.0087305","article-title":"Two types of antibodies are induced by vaccination with A\/California\/2009 pdm virus: binding near the sialic acid-binding pocket and neutralizing both H1N1 and H5N1 viruses","volume":"9","author":"Ohshima","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0019","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/jcm.28.6.1308-1313.1990","article-title":"Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system","volume":"28","author":"Okuno","year":"1990","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/trf.16161","article-title":"Neutralizing and binding activities against SARS-CoV-1\/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan","volume":"61","author":"Kubota-Koketsu","year":"2021","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0021","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/147323000503300606","article-title":"DNA vaccine against hamster oral papillomavirus-associated oral cancer","volume":"33","author":"Maeda","year":"2005","journal-title":"J Int Med Res"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061871","article-title":"Performance Assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories","volume":"9","author":"Etievant","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/v12060686","article-title":"Development and Evaluation of a duo SARS-CoV-2 RT-qPCR assay combining two assays approved by the world health organization targeting the envelope and the RNA-dependant RNA polymerase (RdRp) coding regions","volume":"12","author":"Pezzi","year":"2020","journal-title":"Viruses"},{"issue":"6891","key":"10.1016\/j.retram.2022.103348_bib0024","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"7047","key":"10.1016\/j.retram.2022.103348_bib0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"issue":"7179","key":"10.1016\/j.retram.2022.103348_bib0026","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature06537","article-title":"TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines","volume":"451","author":"Ishii","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2015.4.1.1","article-title":"Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases","volume":"4","author":"Grunwald","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"issue":"13","key":"10.1016\/j.retram.2022.103348_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(99)00391-6","article-title":"Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate","volume":"18","author":"Wang","year":"2000","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.retram.2022.103348_bib0029","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-00279-z","article-title":"Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters","volume":"6","author":"Brocato","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"9","key":"10.1016\/j.retram.2022.103348_bib0031","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"28","key":"10.1016\/j.retram.2022.103348_bib0032","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.retram.2022.103348_bib0033","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.retram.2022.103348_bib0034","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.retram.2022.103348_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clim.2013.08.010","article-title":"Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform","volume":"149","author":"Gottlieb","year":"2013","journal-title":"Clin Immunol"},{"issue":"221","key":"10.1016\/j.retram.2022.103348_bib0036","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007323","article-title":"Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions","volume":"6","author":"Maldonado","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.retram.2022.103348_bib0037","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1398878","article-title":"Trial watch: dNA-based vaccines for oncological indications","volume":"6","author":"Pierini","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.retram.2022.103348_bib0038","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon(R) Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"issue":"10008","key":"10.1016\/j.retram.2022.103348_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"3\u20134","key":"10.1016\/j.retram.2022.103348_bib0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000453264","article-title":"Enhanced prophylactic and therapeutic effects of polylysine-modified Ara h 2 DNA vaccine in a mouse model of peanut allergy","volume":"171","author":"Zhu","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"16","key":"10.1016\/j.retram.2022.103348_bib0041","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735.2003","article-title":"Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.retram.2022.103348_bib0042","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.retram.2022.103348_bib0043","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.retram.2022.103348_bib0044","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.retram.2022.103348_bib0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.retram.2022.103348_bib0046","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.4161\/hv.28077","article-title":"Safety and efficacy of DNA vaccines: plasmids vs. minicircles","volume":"10","author":"Stenler","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.retram.2022.103348_bib0047","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1586\/14779072.2014.955850","article-title":"Beperminogene perplasmid for the treatment of critical limb ischemia","volume":"12","author":"Suda","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"29","key":"10.1016\/j.retram.2022.103348_bib0048","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.vaccine.2019.05.054","article-title":"Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses","volume":"37","author":"Jiang","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.retram.2022.103348_bib0049","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/hum.2018.241","article-title":"Active Immunoprophylaxis and Vaccine Augmentations Mediated by a Novel Plasmid DNA Formulation","volume":"30","author":"Schommer","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.retram.2022.103348_bib0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.retram.2022.103348_bib0051","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1517\/17425247.2015.1077559","article-title":"Nucleic acid vaccination strategies against infectious diseases","volume":"12","author":"Marc","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.PLAS-0028-2014","article-title":"Using plasmids as DNA vaccines for infectious diseases","volume":"2","author":"Tregoning","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.retram.2022.103348_bib0053","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156652321403140819122538","article-title":"Improving DNA vaccine performance through vector design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr Gene Ther"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0054","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.retram.2022.103348_bib0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"17","key":"10.1016\/j.retram.2022.103348_bib0057","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0058","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.retram.2022.103348_bib0059","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.retram.2022.103348_bib0060","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2022.103348_bib0061","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMsr2105280","article-title":"SARS-CoV-2 Variants and Vaccines","author":"Krause","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.retram.2022.103348_bib0062","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.retram.2022.103348_bib0063","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.retram.2022.103348_bib0064","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.retram.2022.103348_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637651","article-title":"The Case for S2: the potential benefits of the S2 Subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 Pandemic","volume":"12","author":"Shah","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.retram.2022.103348_bib0066","doi-asserted-by":"crossref","first-page":"e50366","DOI":"10.1371\/journal.pone.0050366","article-title":"Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing","volume":"7","author":"Elshabrawy","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0067","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41594-021-00596-4","article-title":"Structural basis for broad coronavirus neutralization","volume":"28","author":"Sauer","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.retram.2022.103348_bib0068","article-title":"Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees","author":"Tarke","year":"2021","journal-title":"bioRxiv"},{"issue":"30","key":"10.1016\/j.retram.2022.103348_bib0069","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.retram.2022.103348_bib0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fimmu.2016.00427","article-title":"Modulation of primary immune response by different vaccine adjuvants","volume":"7","author":"Ciabattini","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.retram.2022.103348_bib0071","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2021.04.006","article-title":"Cytokine-skewed Tfh cells: functional consequences for B cell help","volume":"42","author":"Olatunde","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.retram.2022.103348_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.retram.2022.103348_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:40:39Z","timestamp":1762821639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318622000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2452318622000162"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2022.103348","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.21.347799","asserted-by":"object"}]},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical study of a DNA vaccine targeting SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2022.103348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103348"}}